Johnson & Johnson (JNJ) : The consensus on Johnson & Johnson (JNJ) based on 19 analyst recommendation on the company stock is 2.26, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 9 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Johnson & Johnson (JNJ) : The most positive equity analysts on Johnson & Johnson (JNJ) expects the shares to touch $142, whereas, the least positive believes that the stock will trade at $93 in the short term. The company is covered by 13 Wall Street Brokerage Firms. The average price target for shares are $125 with an expected fluctuation of $14.48 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Johnson & Johnson (NYSE:JNJ): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $123.85 and $123.47 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $124.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $123.77, notching a gain of 0.33% for the day. The total traded volume was 4,051,971 . The stock had closed at $123.36 on the previous day.
In a related news,The officer (Exec VP, Finance; CFO) of Johnson & Johnson, Caruso Dominic J sold 41,146 shares at $125.01 on July 26, 2016. The Insider selling transaction had a total value worth of $5,143,661. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.